The firm's suite of tests, based on its Factorial system, produce cellular signatures offering clues to a compound's toxicity and the types of pathways it perturbs.
Collaborators said that the test is accurate and reliable for the rapid detection of the most common gram-positive bacteria responsible for bloodstream infections.
Amplidiag CarbaR+MCR detects the main carbapenemase-producing organisms and colistin resistance markers. Novidiag Bacterial GE+ identifies the most common enteric pathogens.
In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.
The technologies monitor patient response to immunotherapies.
Using Luminex's FlexMap detector, the method allows quantification of cells in a mixture of up to hundreds of individual cells lines treated with drugs in vitro.
Bio-Techne is the second firm to sign an instrument distribution deal with Luminex in recent weeks and will continue to develop assays for the Luminex platform.
The sensor features a DNA-based steric hindrance method, and can detect the presence of antibodies in whole blood in less than 10 minutes.
The partners will work together to develop serological assays measuring antibodies to determine patient immunity to diseases for which vaccines exist.
Abcam was encouraged to buy Firefly BioWorks by its customers, who are more frequently complementing their protein analysis work with miRNA studies.
The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.
A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.
Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.
In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.